Biosynthesis of isoprenoids via the non-mevalonate pathway
Top Cited Papers
- 1 June 2004
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 61 (12) , 1401-1426
- https://doi.org/10.1007/s00018-004-3381-z
Abstract
The mevalonate pathway for the biosynthesis of the universal terpenoid precursors, isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), is known in considerable detail. Only recently, the existence of a second mevalonate-independent pathway for the biosynthesis of IPP and DMAPP was detected in plants and certain eubacteria. Experiments with 13C and/or 2H-labelled precursors were crucial in the elucidation of this novel route. The pathway is essential in plants, many eubacteria and apicomplexan parasites, but not in archaea and animals. The genes, enzymes and intermediates of this pathway were rapidly unravelled over the past few years. Detailed knowledge about the mechanisms of this novel route may benefit the development of novel antibiotics, antimalarials and herbicides.Keywords
This publication has 22 references indexed in Scilit:
- Impact of High‐Dose Atorvastatin in Coronary Heart Disease Patients Age 65 to 78 YearsClinical Cardiology, 2009
- Cardiovascular Prevention in Clinical Practice (ESC and German Guidelines 2007)Herz, 2009
- Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic StenosisNew England Journal of Medicine, 2008
- Simvastatin and Ezetimibe in Addition to Nonpharmacological Risk Factor Modification for Achieving New Low-Density Lipoprotein Cholesterol TargetsHerz, 2008
- The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trialsCMAJ : Canadian Medical Association Journal, 2008
- High-Dose Atorvastatin after Stroke or Transient Ischemic AttackNew England Journal of Medicine, 2006
- Effect of Very High-Intensity Statin Therapy on Regression of Coronary AtherosclerosisJAMA, 2006
- Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2005
- Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary SyndromesJAMA, 2004
- Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary AtherosclerosisJAMA, 2004